Cognition Therapeutics (NASDAQ: CGTX)
$2.40
(-8.0%)
-$0.21
Price as of September 8, 2025, 4:00 p.m. ET
Cognition Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cognition Therapeutics Company Info
Cognition Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for central nervous system disorders. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
News & Analysis
Featured Article
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
Almost all of it was event-driven, while the bulk of these gains were made by small biopharma names.
James Brumley | Sep 3, 2025
Featured Article
Cognition (CGTX) Q2 Grant Income Jumps
Motley Fool Markets Team | Aug 8, 2025
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.